Screener Summaries Updates Institutions Sign In More Updates › Other Events › PLRZ Other Events · Jun 29, 2026
On June 29, 2026, Polyrizon Ltd. announced it received Central Institutional Review Board (IRB) approval for its… PLRZ Polyrizon Ltd.
On June 29, 2026, Polyrizon Ltd. announced it received Central Institutional Review Board (IRB) approval for its Allergy Blocker clinical trial. The company operates in the biotechnology industry and develops medical treatments.
More from Polyrizon Ltd. Polyrizon completes enrollment of all 120 patients in U.S. clinical study of NASARIX Allergy Blocker Oct 27, 2026 Polyrizon Ltd. filed its interim condensed financial statements and management discussion for the six months ended… Sep 28, 2026 Polyrizon Ltd. closed a registered direct offering and concurrent private placement on September 4, 2026, raising… Sep 4, 2026 On September 3, 2026, Polyrizon Ltd. entered into a securities purchase agreement to raise approximately $4.0 million… Sep 4, 2026 Polyrizon Ltd. announced on August 20, 2026, that it has completed contracting with all five U.S. clinical sites for… Aug 20, 2026 All content on this site is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.
Financial data is obtained from public filings and third-party providers and is provided “as-is” without any guarantee of accuracy, completeness, or timeliness.
© 2026 go-intrinsic.com. All rights reserved.
